Study of the effects of interferon α on several human hepatoma cell lines: Analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation

Liver International

Volumn 24, Issue 2, 2004, Pages 149-160

  Legrand, A ^a   Vadrot, N ^a   Lardeux, B ^a   Bringuier, A F ^a   Guillot, R ^a   Feldmann, G ^a  

^a INSERM   (France)

Author keywords

Apoptosis; Human hepatoma cell line; Interferon alpha; Proliferation

Indexed keywords

CYTOKINE; HEAT SHOCK PROTEIN 70; INDUCIBLE NITRIC OXIDE SYNTHASE; NUCLEAR PROTEIN; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; RECOMBINANT ALPHA INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; GEL MOBILITY SHIFT ASSAY; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 2342635289     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.00899.x     Document Type: Article

References (56)

1. Stark G R, Kerr I M, Williams B R G, et al. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-64.
2. Alberti A, Brunetto M R, Colombo M, Craxi A. Recent progress and new trends in the treatment of hepatitis B. J Med Virol 2002; 67: 458-62.
3. Di Bisceglie A M, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
4. Valla D, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-5.
5. Hasan F, Jeffers L J, De Medina M, et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990; 12: 589-91.
6. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27: 201-5.
7. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-7.
8. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
9. Bonino F, Oliveri F, Colombatto P, Brunetto M R. Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. J Viral Hepat 1997; 4 Suppl 2: 79-82.
10. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129: 94-9.
11. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
12. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196-7.
13. Toyoda H, Kumada T, Nakano S, et al. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C. Oncology 2001; 61: 134-42.
14. Hayashi K, Kumada T, Nakano S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy. Hepatogastroenterology 2002; 49: 508-12.
15. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306.
16. Miyaguchi S, Watanabe T, Takahashi H, et al. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002; 49: 724-9.
17. Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options Oncol 2001; 2: 473-83.
18. Gutterman J U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-205.
19. Dunk A A, Ikeda T, Pignatelli M, Thomas H C. Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986; 2: 419-29.
20. Yano H, Iemura A, Haramaki M, et al. Interferon alpha receptor expression and growth inhibition by interferon alpha in human liver cancer cell lines. Hepatology 1999; 29: 1708-17.
21. Murphy D, Detjen K M, Welzel M, et al. Interferon-α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001; 33: 346-56.
22. Der S D, Zhou A, Williams B R G, Silverman R H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-8.
23. IP1 mediated by STAT1. Science 1996; 272: 719-22.
24. WAF1 promoter region. Cancer Res 2000; 60: 3290-99.
25. 2-dependent activation of Nuclear Factor κ B. J Biol Chem 2001; 276: 8918-23.
26. Lopez-Collazo E, Hortelano S, Bosca L. Interferon-alpha/beta inhibits the apoptosis induced by lipopolysaccharide and interferon-gamma in murine peritoneal macro-phages. J Interferon Cytokine Res 1998; 18: 461-7.
27. Arany I, Brysk M M, Brysk H, Tyring S K. Regulation of inducible nitric oxide synthase mRNA levels by differentiation and cytokines in human keratinocytes. Biochem Biophys Res Commun 1996; 220: 618-22.
28. Moreau R. Are nitric oxide synthetases new players in the pathophysiology of fulminant hepatic failure? J. Hepatol 2002; 37: 678-80.
29. Kim Y M, de Vera M E, Watkins S C, Billiar T R. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-α -induced apoptosis by heat shock protein 70 expression. J Biol Chem 1997; 272: 1402-11.
30. Romeo G, Fiorucci G, Chiantore M V, et al. IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 2002; 22: 39-47.
31. Tanaka N, Ishihara M, Kitagawa M, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829-39.
32. Tamura T, Ishihara M, Lamphier M S, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995; 376: 596-9.
33. Giandomenico V, Lancillotti F, Fiorucci G, et al. Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous cell carcinoma cell lines: role of IRF-1 and TGase II-dependent pathways. Cell Growth Differ 1997; 8: 91-100.
34. Harada H, Kitagawa M, Tanaka N, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factor-1 and 2. Science 1993; 259: 971-4.
35. Jourdan M, de Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Diff 2000; 7: 1244-52.
36. Yanase N, Ohshima K, Ikegami H, Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Int Cytokine Res 2000; 20: 1121-9.
37. Lamboley C, Bringuier A F, Camus E, et al. Over-expression of the mouse Fas gene in human Hep3B hepatoma. cells overcomes their resistance to Fas-mediated apoptosis. J. Hepatol 2002; 36: 385-94.
38. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980; 102: 344-52.
39. Andrews N C, Faller D V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucl Acids Res 1991; 19: 2499-500.
40. Sadowski H B, Gilman M Z. Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature 1993; 362: 79-83.
41. Nadori F, Lardeux B, Rahmani M, et al. Presence of distinct AP-1 dimers in normal and transformed rat hepatocytes under basal conditions and after epidermal growth factor stimulation. Hepatology 1997; 26: 1477-83.
42. Lamboley C, Bringuier A F, Feldmann G. Apoptotic behaviour of hepatic and extra-hepatic tumor cell lines differs after fas stimulation. Cell Mol Biol 2000; 46: 13-28.
43. Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-13.
44. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
45. Shin E C, Shin W C, Choi Y, et al. Effect of interferon-gamma on the susceptibility to Fas (CD95/APO1)-mediated cell death in human hepatoma cells. Cancer Immunol Immunother 2001; 50: 23-30.
46. Otsuki T, Yamada O, Sakaguchi H, et al. Human myeloma cell apoptosis induced by interferon-alpha. Br J Haematol 1998; 103: 518-29.
47. Zella D, Barabitskaja O, Casareto L, et al. Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. J Immunol 1999; 163: 3169-75.
48. Xanthoudakis S, Nicholson DW. Heat-shock proteins as death determinants. Nature Cell Biology 2000; 2: E163-5.
49. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003; 195: 158-67.
50. Takaki A, Koike K, Shiraha H, et al. Interferon alpha 8 and 2 show differential activation of apoptosis pathway and growth factor pathway in human hepatoma cell lines. Hepatology 2003; 38(Suppl. 1): 406A.
51. Evan G, Vousden K H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-8.
52. Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatocellular carcinoma. Hepato-gastroenterology 2003; 50: 242-9.
53. Takimoto M, Ohkoshi S, Ichida T, et al. Interferon inhibits progression of liver fibrosis and reduce the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002; 47: 170-6.
54. Melen K, Keskinen P, Lehtonen A, Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J Hepatol 2000; 33: 764-72.
55. Radaeva S, Jaruga B, Hong F, et al. Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 2002; 122: 1020-34.
56. Tada S, Saito H, Tsunematsu S, et al. Interferon regulatory factor-1 gene abnormality and loss of growth inhibitory effect of interferon-alpha in human hepatoma cell lines. Int J Oncol 1998; 13: 1207-16.